Outcomes of Anti-Vascular Endothelial Growth Factor Treatment for Foveal Serous Retinal Detachment Associated with Inferior Staphyloma
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose: To evaluate the efficacy of anti-vascular endothelial growth factor (VEGF) treatment of eyes with fovealserous retinal detachment (SRD) associated with inferior staphyloma and to investigate choroidal thicknesschanges following anti-VEGF therapy. Methods: In this observational case series, eyes with inferior staphyloma accompanied by foveal SRD weretreated with a single intravitreal anti-VEGF injection, followed by further injections as needed. Changes inheight and width of subretinal fluid (SRF) and visual acuity after treatment were assessed. Choroidal thicknesswas measured at the subfovea, 1.5 mm superior and inferior to the fovea using enhanced depth imagingoptical coherence tomography at baseline and 1 month after initial anti-VEGF therapy. Results: Six eyes from six patients were included. One month after the initial injection, the mean SRF heightand width had decreased significantly from 112.5 ± 40.1 to 44.5 ± 48.7 μm (p = 0.046) and from 1,401.8 ±627.3 to 690.7 ± 634.7 μm (p = 0.028), respectively. Mean choroidal thickness at the superior point decreasedfrom 218.7 ± 59.3 to 200.5 ± 61.0 μm (p = 0.046). SRF resolved completely in three of the six eyes (50%) witha mean of 6.8 ± 5.9 injections (range, 1 to 15). All eyes experienced at least one recurrence of exudation, at amean interval of 4.8 months. Mean visual acuity improvement was 0.17 logarithm of the minimum angle of resolutionunits at a mean of 28.7 months follow-up. Conclusions: Anti-VEGF therapy resulted in an SRF decrease and modest visual improvement in eyes with fovealSRD associated with inferior staphyloma. Reduction in superior choroidal thickness appeared to contributeto the clinical improvements that were observed.
Abstract
Purpose: To evaluate the efficacy of anti-vascular endothelial growth factor (VEGF) treatment of eyes with fovealserous retinal detachment (SRD) associated with inferior staphyloma and to investigate choroidal thicknesschanges following anti-VEGF therapy. Methods: In this observational case series, eyes with inferior staphyloma accompanied by foveal SRD weretreated with a single intravitreal anti-VEGF injection, followed by further injections as needed. Changes inheight and width of subretinal fluid (SRF) and visual acuity after treatment were assessed. Choroidal thicknesswas measured at the subfovea, 1.5 mm superior and inferior to the fovea using enhanced depth imagingoptical coherence tomography at baseline and 1 month after initial anti-VEGF therapy. Results: Six eyes from six patients were included. One month after the initial injection, the mean SRF heightand width had decreased significantly from 112.5 ± 40.1 to 44.5 ± 48.7 μm (p = 0.046) and from 1,401.8 ±627.3 to 690.7 ± 634.7 μm (p = 0.028), respectively. Mean choroidal thickness at the superior point decreasedfrom 218.7 ± 59.3 to 200.5 ± 61.0 μm (p = 0.046). SRF resolved completely in three of the six eyes (50%) witha mean of 6.8 ± 5.9 injections (range, 1 to 15). All eyes experienced at least one recurrence of exudation, at amean interval of 4.8 months. Mean visual acuity improvement was 0.17 logarithm of the minimum angle of resolutionunits at a mean of 28.7 months follow-up. Conclusions: Anti-VEGF therapy resulted in an SRF decrease and modest visual improvement in eyes with fovealSRD associated with inferior staphyloma. Reduction in superior choroidal thickness appeared to contributeto the clinical improvements that were observed.
참고문헌 (22)
- Curtin BJ, "The posterior staphyloma of pathologic myopia", Trans Am Ophthalmol Soc, 75, pp.67~86 (1977)
- Apple DJ, "Congenital anomalies of the optic disc", Surv Ophthalmol, 27, pp.3~41 (1982)
- Tosti G, "Serous macular detachment and tilted disc syndrome", Ophthalmology, 106, pp.1453~1455 (1999)
- Leys AM, "Subretinal leakage in myopic eyes with a posterior staphyloma or tilted disk syndrome", Retina, 22, pp.659~665 (2002)
- Theodossiadis PG, "Optical coherence tomography study of tilted optic disk associated with macular detachment", Graefes Arch Clin Exp Ophthalmol, 244, pp.122~124 (2006)
- Nakanishi H, "Macular complications on the border of an inferior staphyloma associated with tilted disc syndrome", Retina, 28, pp.1493~1501 (2008)
- Cohen SY, "Macular serous retinal detachment caused by subretinal leakage in tilted disc syndrome", Ophthalmology, 105, pp.1831~1834 (1998)
- Brown DM, "Ranibizumab versus verteporfin for neovascular age-related macular degeneration", N Engl J Med, 355, pp.1432~1444 (2006)
- Rosenfeld PJ, "Ranibizumab for neovascular age-related macular degeneration", N Engl J Med, 355, pp.1419~1431 (2006)
- Ikuno Y, "Intravitreal bevacizumab for choroidal neovascularization attributable to pathological myopia : one-year results", Am J Ophthalmol, 147, pp.94~100 (2009)
- Silva RM, "Intravitreal ranibizumab for myopic choroidal neovascularization : 12-month results", Retina, 30, pp.407~412 (2010)
- Milani P, "Bevacizumab for macular serous neuroretinal detachment in tilted disk syndrome", J Ophthalmol, 2010, pp.970580~ (2010)
- Donati MC, "Treatment of macular serous neuroretinal detachment in tilted disk syndrome : report of 3 cases", Eur J Ophthalmol, 23, pp.267~270 (2013)
- Spaide RF, "Enhanced depth imaging spectral-domain optical coherence tomography", Am J Ophthalmol, 146, pp.496~500 (2008)
- Hirata M, "Macular choroidal thickness and volume in normal subjects measured by swept-source optical coherence tomography", Invest Ophthalmol Vis Sci, 52, pp.4971~4978 (2011)
- Yamagishi T, "Choroidal thickness in inferior staphyloma associated with posterior serous retinal detachment", Retina, 32, pp.1237~1242 (2012)
- Ellabban AA, "Macular choroidal thickness measured by swept source optical coherence tomography in eyes with inferior posterior staphyloma", Invest Ophthalmol Vis Sci, 53, pp.7735~7745 (2012)
- Maruko I, "Morphologic choroidal and scleral changes at the macula in tilted disc syndrome with staphyloma using optical coherence tomography", Invest Ophthalmol Vis Sci, 52, pp.8763~8768 (2011)
- Murakami T, "Occludin phosphorylation and ubiquitination regulate tight junction trafficking and vascular endothelial growth factor-induced permeability", J Biol Chem, 284, pp.21036~21046 (2009)
- Nicoletti VG, "Diabetic patients and retinal proliferation : an evaluation of the role of vascular endothelial growth factor(VEGF)", Exp Clin Endocrinol Diabetes, 111, pp.209~214 (2003)
- Saenz-de-Viteri M, "Single-and repeated-dose toxicity study of bevacizumab, ranibizumab, and aflibercept in ARPE-19 cells under normal and oxidative stress conditions", Biochem Pharmacol, 103, pp.129~139 (2016)
- Hirano Y, "Resolution of exudative changes refractory to ranibizumab after aflibercept injections at the margin of inferior staphyloma in tilted disc syndrome", Ophthalmic Surg Lasers Imaging Retina, 46, pp.384~386 (2015)